Keyword: Impax Laboratories
Legend teams with J&J on CAR-T project, Eisai and Biogen's Alzheimer's drug fails in early readout, Impax and Bora Pharma ink deal.
Impax Laboratories will sell its manufacturing site in Taiwan to Bora Pharmaceuticals for $18.5 million and take a charge of up to $80 million.
Ahead of an expected merger, the combined company of Amneal-plus-Impax has a new CEO.
For evidence that a pricing scandal can translate into real lost sales for a pharmaceutical company, look no further than Mylan's third-quarter results.
Surprise, surprise: Impax Labs, looking to bulk up amid generics pricing pressure and newly helmed by M&A specialist Paul Bisaro, has struck a deal.
Reports have said Impax could bulk up in the face of generics pricing pressure. And at least one analyst says Endo should follow suit.
Impax Labs CEO Paul Bisaro, who has extensive experience building companies through M&A, is reportedly in talks with competitor Amneal.
Mylan agreed to pay $465M to settle a federal probe into underpaid Medicaid rebates, but that's less than half the cost to taxpayers, HHS says.
Two former Heritage Pharma execs will cooperate with a broad generic pricing probe that's roped in some of the biggest companies in the business.
Former Allergan Chairman Paul Bisaro will use his tested strategy of M&A and consolidation in his efforts to restore Impax Laboratories' fiscal health, only this time in reverse.